June 29th 2025
Results from Invivyd’s pemivibart (Pemgarda) phase 3 trial show it had a significant PrEP effect during the 6-month on-drug period for both immunocompromised and immunocompetent populations.
June 25th 2025
New epidemiologic data, vaccine effectiveness, and safety assessments guide a move from universal to targeted vaccination recommendations for the 2025–26 season.
June 12th 2025
Although COVID-19 has receded quite a bit from the minds of many, it still remains a virus that can present serious morbidity and mortality. Here is a review of clinical treatment strategies by an intensivist when seeing patients with severe COVID-19.
June 12th 2025
Phase 3 results show immune response and tolerability in adults 65 and older, following phase 2 findings.
May 31st 2025
The company's vaccine, mRNA-1283, becomes the first approval under the new federal guidelines.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control
October 7, 2025
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
Increased Healthcare-Associated Infections: The COVID-19 Impact on Hospital Infection Prevention
April 22nd 2024Monika Pogorzelska-Maziarz, epidemiologist, health services researcher, and associate professor at Thomas Jefferson University, shares insights on COVID-19's influence in acute care hospitals at this year’s Society for Healthcare Epidemiology of America (SHEA) conference.
Watch
CDC ACIP Votes to Recommend an Additional Dose of COVID-19 Vaccine in Seniors
February 28th 2024With today's vote, the federal agency’s Advisory Committee on Immunization Practices (ACIP) is now recommending people 65 years of age and older get 1 more dose of the 2023-2024 formula of the COVID-19 vaccine.
Read More
2 Commerce Drive
Cranbury, NJ 08512